Jules O'Rear

TL;DR: This work proposes five “standard” categories that encompass all stages of viral genome finishing, and they are defined using simple criteria that are agnostic to the technology used for sequencing.

TL;DR: It is concluded that CMV load is an appropriate surrogate endpoint for CMV trials in organ transplant recipients due to low frequency of disease and several lines of evidence support the validity of viral load.

TL;DR: This research presents a novel and scalable approach called “sequencing-based annotation-based phenotype analysis” (SAWG-PAWG) for HCV Drug Development Advisory Group HCV DRAG, which aims to provide real-time information about the structure and activity of the HCV “spatially aggregating immune checkpoints”.

TL;DR: The 2019 Virtual SARS-CoV-2 Antiviral Summit as discussed by the authors was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals.

TL;DR: The rationale to support the BOC dosing recommendations in prior P/R-null responders and treatment-naı̈ve BOC late responders is summarized.